我国罕见病及儿童用药市场独占期制度构建研究OA
A Study on the Development of China's Market Exclusivity System for Rare Disease Drugs and Pediatric Medicines
2026年新修订《中华人民共和国药品管理法实施条例》从行政法规层面设立了罕见病及儿童用药市场独占期制度.本文通过文献研究、比较研究、案例分析等方法,系统梳理美国和欧盟罕见病及儿童用药市场独占期制度的主要规定、典型案例及实施效果,结合我国医药产业环境及罕见病、儿童用药上市情况,从独占性质、范畴界定、保护强度、期限设计、供应保障义务及认定起点与终止程序等方面,提出构建我国罕见病及儿童用药市场独占期制度的关键考量因素,以期推动该制度在我国落地实施.
The newly revised Regulations for the Implementation of the Drug Administration Law of the People's Republic of China(2026)established a market exclusivity system for rare disease drugs and pediatric medicines at the level of administrative regulations.Through literature review,comparative analysis,and case studies,this paper systematically examines the key provisions,representative cases,and implementation outcomes of market exclusivity systems for rare disease drugs and pediatric medicines in the United States and the European Union.In light of China's pharmaceutical industry environment and the marketing status of rare disease and pediatric drugs,this paper proposes key considerations for developing China's market exclusivity system,including the nature of exclusivity,scope definition,level of protection,term design,supply assurance obligations,and the starting point and termination procedures of exclusivity.These considerations are intended to facilitate the implementation of this system in China.
谢金平;秦梦芝;赵楠楠;陈芳凝;吴心颖;唐溪;邵蓉
中国药科大学药品监管科学研究院中国药科大学药品监管科学研究院中国药科大学药品监管科学研究院中国药科大学药品监管科学研究院中国药科大学药品监管科学研究院中国药科大学药品监管科学研究院中国药科大学药品监管科学研究院
医药卫生
罕见病用药儿童用药市场独占期制度构建
rare disease drugspediatric medicinesmarket exclusivitysystem development
《中国食品药品监管》 2026 (9)
6-21,16
2025年中国药品监督管理研究会课题(2025-Y-Y-022)
评论